There is another interesting point mentioned by Karim during the conversation with Yasmeen. If I understand correctly, he mentions that the new drug will be the first to pop on the system used by the pharmacists when they fill it. For example, Brand Vascepa came first and Hikama Came in second and Dr Reddy came into the market as third. So when a pharmacist looks to fill Vascepa, Dr. Reddy's generic vascepa will be listed as the first in line and Hikama will be shown as the second and the brand will be at the bottom and that is how the switch happens. It makes sense and he acknowledged that it creates such a big challenge. So if he is right, we should start to see Apotex slowly taking scripts away from Hikama and Dr. Reddys'. One thing I do like about Karim after hearing that chat is that he is not sugar coating anything. He sure does states the challenges up front and also he mentions that Europe will take some time to develop. My question is that if there is so many challenges, why not hand this drug over to someone who is capable. Not many small biopharma have done what Amarin is trying to do. I think it is utter stupidity to do this with just one drug..
Market Data 
Markets 
AI
